Nutraceutical composition and method for promoting the rejuvenation of cells in warm-blooded animals including humans

Abstract

A nutraceutical composition and method for promoting the rejuvenation of cells in warm-blooded animals including humans employing mitochondrial energy production-inducing agent for inducing the mitochondrial energy production to proceed from a lower energy production state to a higher energy production state and a nutraceutical composition for supporting the metabolic requirements of the increased mitochondrial energy production induced by the mitochondrial energy production-inducing agent.

1 . A method for rejuvenating cells having a lower energy production state to a higher energy production state in a warm-blooded animal including a human, said method comprising the steps of:
 inducing the lower energy production state cells to increase mitochondrial energy production toward said higher energy production state; and   supplying a nutraceutical composition for uptake by the higher energy production state cells in amounts sufficient to satisfy the metabolic requirements resulting from the increase in mitochondrial energy production.   
   
   
       2 . The method of  claim 1  further comprising:
 stimulating the lower energy production state cells to increase production of adenosine triphosphate, wherein the nutraceutical composition satisfies the metabolic requirements resulting from the increased production of adenosine triphosphate in the cells.   
   
   
       3 . The method of  claim 1  further comprising:
 generating an induced energy nutrient deficient state in the mitochondria, wherein the nutraceutical composition satisfies the metabolic requirements of the induced energy nutrient deficient state in the mitochondria.   
   
   
       4 . The method of  claim 1  wherein the step of inducing the cells to increase mitochondrial energy production comprises administering a mitochondrial energy production-inducing agent to the cells. 
   
   
       5 . The method of  claim 1  further comprising:
 measuring the progress of cell rejuvenation attained, and   adjusting the level of mitochondrial energy production for optimizing the cell rejuvenation progress in slowing or reversing the effects of ageing.   
   
   
       6 . The method of  claim 4  wherein the mitochondrial energy production-inducing agent is a hormone. 
   
   
       7 . The method of  claim 6  wherein the hormone is selected from the group consisting of growth hormone, a steroid, and mixtures thereof. 
   
   
       8 . The method of  claim 7  wherein the hormone is selected from the group consisting of recombinant human growth hormone (rhGH), testosterone, and mixtures thereof. 
   
   
       9 . The method of  claim 8  wherein an effective amount of the testosterone is administered to the patient to maintain a testosterone blood concentration of at least 500 ng/dL. 
   
   
       10 . The method of  claim 9  wherein the testosterone blood concentration is from about 500 ng/dL to 1000 ng/dL. 
   
   
       11 . The method of  claim 8  wherein the recombinant human growth hormone (rhGH) is administered at a dosage regimen of at least 2.5 μg/kg/day. 
   
   
       12 . The method of  claim 11  wherein the recombinant human growth hormone (rhGH) is administered at a dosage regimen of from about 2.5 μg/kg/day to 5 μg/kg/day. 
   
   
       13 . The method of  claim 1  wherein the nutraceutical composition comprises an energy nutrient capable of supplying the nutrients needed to meet and sustain the higher energy production state. 
   
   
       14 . The method of  claim 13  further comprising:
 measuring the progress of cell rejuvenation attained, and   adjusting the formulation of the energy nutrients in the nutraceutical composition for optimizing the cell rejuvenation progress in slowing or reversing the effects of ageing.   
   
   
       15 . The method of  claim 13  wherein the energy nutrient is selected from the group consisting of a water-soluble energy nutrient, a fat-soluble energy nutrient, and mixtures thereof. 
   
   
       16 . The method of  claim 15  further comprising administering a dosage regimen, wherein an effective amount of each of said water-soluble energy nutrient and fat-soluble energy nutrient is maintained in the body of the warm-blooded animal including human. 
   
   
       17 . The method of  claim 16  wherein the water-soluble energy nutrient is selected from the group consisting of carnitine, magnesium, vitamin C, selenium and mixtures thereof, 
   
   
       18 . The method of  claim 15  wherein the fat-soluble energy nutrient is selected from the group consisting of tocopherols, carotenoids, coenzyme Q10, alpha-lipoic acid, and mixtures thereof. 
   
   
       19 . The method of  claim 15  further comprising varying over a period of time the effective dosage amounts of at least one of said water-soluble energy nutrient and fat-soluble energy nutrient for avoiding potentially adverse effects associated with excess stores of the fat-soluble energy nutrient in the body of the warm-blooded animal including human. 
   
   
       20 . The method of  claim 13  wherein the energy nutrient is selected from the group consisting of amino acids, quaternary amines, vitamins, dietary minerals, chelating agents, enzymes, ubiquinones, antioxidants, essential fatty acids, carotenoids, tocopherols, and mixtures thereof. 
   
   
       21 . The method of  claim 20  wherein the energy nutrient is selected from the group consisting of carnitine, magnesium, vitamin C, selenium, coenzyme Q10, α-lipoic acid, vitamin E, beta-carotene, and mixtures thereof. 
   
   
       22 . The method of  claim 1  wherein the nutraceutical composition comprises:
 carnitine in an amount of from about 50 mg to 15,000 mg;   magnesium in an amount of from about 10 mg to 2,000 mg;   vitamin C in an amount of from about 10 mg to 1,000 mg;   selenium in an amount of from about 5 ug to 500 ug;   coenzyme Q10 in an amount of from about 5 mg to 500 mg;   α-lipoic acid in an amount of from about 5 mg to 600 mg;   at least one tocopherol in an amount of from about 5 mg to 800 mg; and   at least one carotenoid in an amount of from about 1 mg to 600 mg.   
   
   
       23 . The method of  claim 22  wherein the nutraceutical composition comprises:
 carnitine in an amount of from about 100 mg to 10,000 mg;   magnesium in an amount of from about 50 mg to 1,000 mg;   vitamin C in an amount of from about 50 mg to 600 mg;   selenium in an amount of from about 10 ug to 400 ug;   coenzyme Q10 in an amount of from about 10 mg to 400 mg;   α-lipoic acid in an amount of from about 10 mg to 250 mg;   at least one tocopherol in an amount of from about 10 mg to 500 mg; and   at least one carotenoid in an amount of from about 3 mg to 500 mg.   
   
   
       24 . A nutraceutical composition for administration to a patient having received a mitochondrial energy production-inducing agent to elevate the energy production for the mitochondria from a lower energy production state to a higher energy production state, wherein the existence of the higher energy production state results in a deficiency of energy nutrients necessary to sustain the higher energy production state, said composition comprising at least one energy nutrient in an amount effective for supplying the nutrients needed to sustain the higher energy production state, and a nutraceutically acceptable carrier. 
   
   
       25 . The nutraceutical composition of  claim 24  wherein the mitochondrial energy production-inducing agent is a hormone. 
   
   
       26 . The nutraceutical composition of  claim 25  wherein the hormone is selected from the group consisting of growth hormone, a steroid, and mixtures thereof. 
   
   
       27 . The nutraceutical composition of  claim 26  wherein the hormone is selected from the group consisting of recombinant human growth hormone (rhGH), testosterone, and mixtures thereof. 
   
   
       28 . The nutraceutical composition of  claim 27  wherein an effective amount of the testosterone is administered to the patient to maintain a testosterone blood concentration of at least 500 ng/dL. 
   
   
       29 . The nutraceutical composition of  claim 28  wherein the testosterone blood concentration is from about 500 ng/dL to 1000 ng/d L. 
   
   
       30 . The nutraceutical composition of  claim 27  wherein the recombinant human growth hormone (rhGH) is administered at a dosage regimen of at least 2.5 μg/kg/day. 
   
   
       31 . The nutraceutical composition of  claim 30  wherein the human growth hormone is administered at a dosage regimen of from about 2.5 μg/kg/day to 5 μg/kg/day. 
   
   
       32 . The nutraceutical composition of  claim 24  wherein the at least one energy nutrient is selected from the group consisting of a water-soluble energy nutrient, a fat-soluble energy nutrient, and mixtures thereof. 
   
   
       33 . The nutraceutical composition of  claim 32  wherein the water-soluble energy nutrient is selected from carnitine, magnesium, vitamin C, selenium and mixtures thereof. 
   
   
       34 . The nutraceutical composition of  claim 32  wherein the fat-soluble energy portion is selected from the group consisting of tocopherols, carotenoids, coenzyme Q10, alpha-lipoic acid, and mixtures thereof. 
   
   
       35 . The nutraceutical composition of  claim 32  comprising a dosage regimen wherein an effective amount of each of said water-soluble and fat-soluble energy nutrients is maintained in the body. 
   
   
       36 . The nutraceutical composition of  claim 35  wherein the dosage regimen comprises daily amounts of water-soluble energy nutrients and non-daily amounts of fat-soluble energy nutrients. 
   
   
       37 . The nutraceutical composition of  claim 32  wherein said at least one of said water-soluble energy nutrient and fat-soluble energy nutrient are present in effective dosage amounts for avoiding potentially adverse effects associated with excess stores of the fat-soluble energy nutrient in the body of the warm-blooded animal including human. 
   
   
       38 . The nutraceutical composition of  claim 24  wherein the energy nutrient is selected from the group consisting of amino acids, quaternary amines, vitamins, dietary minerals, chelating agents, enzymes, ubiquinones, antioxidants, essential fatty acids, carotenoids, tocopherols, and mixtures thereof. 
   
   
       39 . The nutraceutical composition of  claim 38  wherein the energy nutrient is selected from the group consisting of carnitine, magnesium, vitamin C, selenium, coenzyme Q10, α-lipoic acid, vitamin E, beta-carotene, and mixtures thereof. 
   
   
       40 . The nutraceutical composition of  claim 24  wherein the energy nutrient comprises:
 carnitine in an amount of from about 50 mg to 15,000 mg;   magnesium in an amount of from about 10 mg to 2,000 mg;   vitamin C in an amount of from about 10 mg to 1,000 mg;   selenium in an amount of from about 5 ug to 500 ug;   coenzyme Q10 in an amount of from about 5 mg to 500 mg;   α-lipoic acid in an amount of from about 5 mg to 600 mg;   at least one tocopherol in an amount of from about 5 mg to 800 mg; and   at least one carotenoid in an amount of from about 1 mg to 600 mg.   
   
   
       41 . The nutraceutical composition of  claim 40  wherein the energy nutrient comprises:
 carnitine in an amount of from about 100 mg to 10,000 mg;   magnesium in an amount of from about 50 mg to 1,000 mg;   vitamin C in an amount of from about 50 mg to 600 mg;   selenium in an amount of from about 10 ug to 400 ug;   coenzyme Q10 in an amount of from about 10 mg to 400 mg;   α-lipoic acid in an amount of from about 10 mg to 250 mg;   at least one tocopherol in an amount of from about 10 mg to 500 mg; and   at least one carotenoid in an amount of from about 3 mg to 500 mg.